Inhibikase Therapeutics (IKT) announced the appointment of veteran biopharma executive Timothy Pigot as the Company’s Chief Commercial and Strategy Officer. Most recently Pigot served as Chief Commercial Officer of Aerovate Therapeutics, where he led commercial planning and strategy for the Company’s therapeutic candidate in PAH.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IKT: